KR960003741A - 조골세포 증식인자 - Google Patents

조골세포 증식인자 Download PDF

Info

Publication number
KR960003741A
KR960003741A KR1019950021475A KR19950021475A KR960003741A KR 960003741 A KR960003741 A KR 960003741A KR 1019950021475 A KR1019950021475 A KR 1019950021475A KR 19950021475 A KR19950021475 A KR 19950021475A KR 960003741 A KR960003741 A KR 960003741A
Authority
KR
South Korea
Prior art keywords
human
treating
fracture
proliferation factor
osteoblast proliferation
Prior art date
Application number
KR1019950021475A
Other languages
English (en)
Other versions
KR100361717B1 (ko
Inventor
아키라 구도
도루 나카니시
마사하루 다키가와
Original Assignee
사토 미쓰아키
훽스트 저팬 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사토 미쓰아키, 훽스트 저팬 리미티드 filed Critical 사토 미쓰아키
Publication of KR960003741A publication Critical patent/KR960003741A/ko
Application granted granted Critical
Publication of KR100361717B1 publication Critical patent/KR100361717B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 약제학적으로 허용되는 담체 및 사람 뉴로트로핀－3(NT－3)을 함유하는 골 대사 질환 및/또는 골절용 조성물에 관한 것이다.
본 발명은 또한 유효량의 사람 뉴로트로핀－3(NT－3)을 함유하는 약제를 골 대사 질환 또는 골절의 치료 및/또는 예방이 요구되는 환자에게 투여함을 포함하여 상기 골 대사 질환 또는 골절을 치료/또는 예방하는 방법에 관한 것이다.

Description

조골세포 증식인자
내용없음

Claims (2)

  1. 약제학적으로 허용되는 담체 및 사람 뉴로트로핀－3(neurotrophin : NT－3)을 함유하는 골 대사 질환 또는 골절용 조성물.
  2. 유효량의 사람 뉴트로핀－3(NT－3)을 함유하는 약제를 골 대사 질환 또는 골절의 치료 또는 예방이 요구되는 환자에게 투여함을 포함하며, 골 대사 질환 또는 골절을 치료 및 예방하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950021475A 1994-07-22 1995-07-21 조골세포증식인자 KR100361717B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20125794A JP3738281B2 (ja) 1994-07-22 1994-07-22 新規な骨芽細胞増殖因子
JP94-201257 1994-07-22

Publications (2)

Publication Number Publication Date
KR960003741A true KR960003741A (ko) 1996-02-23
KR100361717B1 KR100361717B1 (ko) 2003-07-07

Family

ID=16437950

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950021475A KR100361717B1 (ko) 1994-07-22 1995-07-21 조골세포증식인자

Country Status (14)

Country Link
US (1) US6080720A (ko)
EP (1) EP0704219B1 (ko)
JP (1) JP3738281B2 (ko)
KR (1) KR100361717B1 (ko)
AT (1) ATE206930T1 (ko)
AU (1) AU693567B2 (ko)
CA (1) CA2154403A1 (ko)
DE (1) DE69523250T2 (ko)
DK (1) DK0704219T3 (ko)
ES (1) ES2161809T3 (ko)
FI (1) FI953514A (ko)
HU (1) HU217082B (ko)
NO (1) NO952912L (ko)
PT (1) PT704219E (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8936804B2 (en) 2010-01-15 2015-01-20 Rutgers, The State University Of New Jersey Use of vanadium compounds to accelerate bone healing
EP2648718B1 (en) 2010-12-10 2019-05-08 Rutgers, the State University of New Jersey Implantable devices coated with insulin-mimetic agent composites and methods thereof
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
US9931348B2 (en) 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
WO1995030434A1 (en) * 1994-05-06 1995-11-16 Regeneron Pharmaceuticals, Inc. Methods based on the role of neurotrophin 3 in female reproduction

Also Published As

Publication number Publication date
DE69523250T2 (de) 2002-07-04
US6080720A (en) 2000-06-27
NO952912D0 (no) 1995-07-21
ES2161809T3 (es) 2001-12-16
FI953514A0 (fi) 1995-07-20
JP3738281B2 (ja) 2006-01-25
HU217082B (hu) 1999-11-29
EP0704219B1 (en) 2001-10-17
DE69523250D1 (de) 2001-11-22
PT704219E (pt) 2002-03-28
DK0704219T3 (da) 2002-02-04
JPH0834744A (ja) 1996-02-06
AU693567B2 (en) 1998-07-02
FI953514A (fi) 1996-01-23
HU9502202D0 (en) 1995-09-28
NO952912L (no) 1996-01-23
HUT73185A (en) 1996-06-28
AU2710595A (en) 1996-02-01
EP0704219A3 (en) 1997-12-10
CA2154403A1 (en) 1996-01-23
ATE206930T1 (de) 2001-11-15
EP0704219A2 (en) 1996-04-03
KR100361717B1 (ko) 2003-07-07

Similar Documents

Publication Publication Date Title
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
UA41989C2 (uk) Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
HUT77380A (hu) Kombinált gyógyszerkészítmény alkalmazása sclerosis multiplex (MS) és más demielizáló állapotok kezelésére
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
BR9710250A (pt) Composto composição farmacêutica e processos para tratar uma infecção bacteriana em um paciente em necessidade de tal tratamento e para produzir um composto de bromotiacumicina
KR960003741A (ko) 조골세포 증식인자
BR9907234A (pt) Polìmeros ligantes de gordura
KR950013519A (ko) 골절 예방 및 치료용 약제
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
KR900017599A (ko) 종양 치료용 약학 조성물
RU94020918A (ru) Способ лечения опсоменореи
RU94033434A (ru) Способ хирургического лечения врожденных грыж спинного мозга
RU2001132588A (ru) Новое применение вещества для пнс
RU94016144A (ru) Средство для лечения больных болезнью рейтера
DE3776662D1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
KR940003550A (ko) 노인성 치매 예방 및 치료방법

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee